Complete resection of liver metastases of colorectal cancer after high efficacy bevacizumab, S-1, and CPT-11 combination chemotherapy

Japanese Journal of Cancer and Chemotherapy

Volumn 42, Issue 1, 2015, Pages 101-104

  Imai, Hiroo ^a   Sawada, Kinya ^a   Sato, Akehumi ^a   Nishi, Kazuya ^a   Sasaki, Takashi ^a   Takahashi, Tom ^a   Ohori, Hisatsügu ^a  

^a Ishinomaki Red Cross Hospital   (Japan)

Author keywords

Bevacizumab; Complete resection; CPT 11; Liver metastases; S 1

Indexed keywords

BEVACIZUMAB; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG COMBINATION; MONOCLONAL ANTIBODY; OTERACIL; S 1 (COMBINATION); TEGAFUR;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; COLONOSCOPY; COLORECTAL CARCINOMA; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; HUMAN; ILEUS; IMAGE ANALYSIS; MALE; RECTUM ANTERIOR RESECTION; TREATMENT OUTCOME; TUMOR BIOPSY; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; DRUG COMBINATION; LIVER NEOPLASMS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SECONDARY; SIGMOID NEOPLASMS;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; HUMANS; LIVER NEOPLASMS; MALE; OXONIC ACID; SIGMOID NEOPLASMS; TEGAFUR;

EID: 84927613056     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Scheele J, Stangl R and Altendorf-Hofmann A: Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 77(11): 1241-1246, 1990.
2. Minagawa M, Makuuchi M, Torzilli G., et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 231 (4): 487-499, 2000.
3. Nordlinger B, Van Cutsem E, Gruenberger T, et al: Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 20 (6): 985-992, 2009.
4. Komatsu Y, Yuki S, Sogabe S., et al: Phase II study of combined treatment with irinotecan and S-l (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). Oncology 80(1-2): 70-75, 2011.
5. Fuchs CS, Marshall J, Mitchell E., et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25 (30): 4779-4786, 2007.
6. Mitry E, Fields AL, Bleiberg H, et al: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials, J Clin Oncol 26(30): 4906-4911, 2008.
7. Hsu DS, Balakumaran BS, Acharya C.R., et al: Retraction. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 28 (35): 5229, 2010.
8. Touil Y, Igoudjil W, Corvaisier M, et al: Colon cancer cells escape 5FU chemotherapy-induced cell death by entering sternness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res 20 (4): 837-846, 2014.
9. O'Connell M.J., Laurie JA, Kahn M, et al: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16(1): 295-300, 1998.
10. Allegra CJ, Yothers G, O'Connell MJ, et al: Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 29(1): 11-16, 2011.